Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458162 | 0.85 | NAMPT (0.56) | EPHX1ALDH1A1HTTMAPTSMN1; SMN2 | |
| SCHEMBL5464819 | 0.84 | EPHX1 (0.58) | EPHX1ALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL5454258 | 0.81 | MAPT (0.67) | ALDH1A1MAPTSMN1; SMN2MAPK1TP53 | |
| SCHEMBL6438783 | 0.80 | EPHX1 (0.84) | EPHX1ALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL11033138 | 0.80 | EPHX1 (0.84) | EPHX1ALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL11034317 | 0.80 | EPHX1 (0.84) | EPHX1ALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL12989307 | 0.80 | MAPT (0.64) | ALDH1A1HTTMAPTSMN1; SMN2EPHX2 | |
| SCHEMBL5460936 | 0.79 | MAPT (0.68) | ALDH1A1HTTMAPTMAPK1POLB | |
| SCHEMBL5020899 | 0.76 | EPHX1 (1.00) | EPHX1ALDH1A1HTTEPHX2KDM4E | |
| SCHEMBL10599308 | 0.76 | EPHX1 (1.00) | EPHX1ALDH1A1HTTEPHX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | EPHX1 4132/4885ALDH1A1 731/4885HTT 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.